Non-Small-Cell Lung Cancer – Landscape & Forecast – Disease Landscape & Forecast

The multi-billion-dollar non-small-cell lung cancer (NSCLC) market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as Keytruda (Merck & Co), which gained label expansion in January 2023 in the adjuvant setting, have broad applicability in many stages and settings of NSCLC and dominate the market, while biomarker-targeted therapeutics increasingly drive segmentation of the space. The range of drug-addressable disease drivers continues to expand, with the entry of KRAS inhibitors and the 2022 approval of Enhertu, the first targeted therapy for previously treated metastatic HER2-mutant NSCLC. Continued drug development in the biomarker and immune checkpoint inhibitor classes, plus further new market entrants, will further drive competition in this commercially lucrative market.

Questions answered

  • How will the recent and expected new market entrants shape the treatment landscapes across the various settings and stages (I-IV) of NSCLC?
  • Which therapy options will dominate the commercially lucrative first-line metastatic NSCLC setting?
  • What are the most promising pipeline products, and what is their forecast uptake and patient share in NSCLC?
  • What are NSCLC’s key market drivers and constraints, and how will the market evolve over the forecast period?

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancements

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents

  • Non-Small-Cell Lung Cancer - Landscape & Forecast - Disease Landscape & Forecast
    • Key Findings
      • Key Updates
        • October 2023
        • September 2023
        • May 2023
        • April 2023
        • December 2022
      • Market Outlook
        • Key findings
          • Major-market share of drug classes in NSCLC: 2022
          • Major-market share of drug classes in NSCLC: 2032
          • Key current therapies in NSCLC: population positioning
          • Emerging therapies in NSCLC: population positioning
          • NSCLC SWOT analysis
        • Market drivers and constraints
          • What factors are driving the market for NSCLC?
          • What factors are constraining the market for NSCLC?
          • Drug-treatable population share and major-market sales share in NSCLC: 2022
          • Drug-treatable population share and major-market sales share in NSCLC: 2032
          • Major-market sales of drug classes in NSCLC: 2022-2032
          • Major-market sales of select drugs in NSCLC: 2022-2032
          • Major-market sales share of select drugs in NSCLC by patient population (all histologies): 2022 and 2032
        • Segment-specific trends
          • Stage IA NSCLC
          • Stage IB-II NSCLC
          • Stage III NSCLC
          • Patient-share dynamics of select therapies in stage III NSCLC (adenocarcinoma), United States: 2022-2032
          • Patient-share dynamics of key regimens in first-line metastatic NSCLC (adenocarcinoma), United States: 2022-2032
          • Patient-share dynamics of immune checkpoint inhibitor-containing regimens in first-line metastatic NSCLC (adenocarcinoma), United States: 2022-2032
          • Patient-share dynamics of key therapies in first-line EGFR-positive metastatic NSCLC (adenocarcinoma), United States: 2022-2032
          • Patient-share dynamics of key therapies in first-line ALK-positive metastatic NSCLC (adenocarcinoma), United States: 2022-2032
          • Patient-share dynamics of key regimens in second-line metastatic NSCLC (adenocarcinoma), United States: 2022-2032
          • Patient-share dynamics of key regimens in third-line metastatic NSCLC (adenocarcinoma), United States: 2022-2032
      • Forecast
        • Market Forecast Assumptions
        • Market Forecast Dashboard
      • Etiology and Pathophysiology
        • Disease overview
          • Disease pathophysiology
            • Progression of NSCLC
            • Anatomy and histology of NSCLC
            • Natural history of NSCLC
            • Timing of genetic changes in NSCLC
          • Staging and classification
            • Classification of NSCLC
            • Staging of NSCLC
          • Key pathways and drug targets
            • Key pathways and drug targets for NSCLC
        • Epidemiology
          • Key findings
            • Epidemiology populations
              • Disease definition, methods, and sources used
              • Diagnosed incident cases of NSCLC by histology: 2022-2032
              • Disease definition, methods, and sources used
              • Diagnosed incident cases of adenocarcinoma by stage at diagnosis: 2022-2032
              • Diagnosed incident cases of squamous cell carcinoma by stage at diagnosis: 2022-2032
              • Diagnosed incident cases of large-cell and other types of NSCLC by stage at diagnosis: 2022-2032
              • Diagnosed incident cases of NOS NSCLC by stage at diagnosis: 2022-2032
              • Disease definition, methods, and sources used
              • Recurrent incident cases of NSCLC by histology: 2022-2032
              • Non-small-cell lung cancer patient flow
              • Drug-treatable cases of adenocarcinoma NSCLC: 2022-2032
              • Drug-treatable cases of large-cell, other, and NOS NSCLC: 2022-2032
              • Drug-treatable cases of squamous cell NSCLC: 2022-2032
              • Drug-treated cases of adenocarcinoma NSCLC: 2022-2032
              • Drug-treated cases of large-cell, other, and NOS NSCLC: 2022-2032
              • Drug-treated cases of squamous cell NSCLC: 2022-2032
          • Current Treatment
            • Key findings
              • Treatment goals
                • Key endpoints used in clinical trials for non-small-cell lung cancer
              • Key current therapies
                • Overview
                • Mechanism of action of key current drug classes used for non-small-cell lung cancer
                • Current treatments used for non-small-cell lung cancer
                • Market events impacting the use of key current therapies in non-small-cell lung cancer
                • Key results from select clinical trials investigating Keytruda for the treatment of non-small-cell lung cancer
                • Ongoing clinical development of Keytruda
                • Key ongoing clinical trials of Keytruda in the treatment of non-small-cell lung cancer
                • Expert insight: Keytruda
                • Key results from select clinical trials investigating Opdivo for the treatment of non-small-cell lung cancer
                • Ongoing clinical development of Opdivo
                • Key ongoing clinical trials of Opdivo in the treatment of non-small-cell lung cancer
                • Key results from select clinical trials investigating Opdivo combination therapies for the treatment of non-small-cell lung cancer
                • Ongoing clinical development of Opdivo combination therapies
                • Key ongoing clinical trials of Opdivo combination therapies in the treatment of non-small-cell lung cancer
                • Expert insight: Opdivo combination therapies
                • Tecentriq
                • Key results from select clinical trials investigating Tecentriq for the treatment of non-small-cell lung cancer
                • Ongoing clinical development of Tecentriq
                • Key ongoing clinical trials of Tecentriq in the treatment of non-small-cell lung cancer
                • Expert insight: Tecentriq
                • Key results from select clinical trials investigating Imfinzi for the treatment of non-small-cell lung cancer
                • Ongoing clinical development of Imfinzi
                • Key ongoing clinical trials of Imfinzi in the treatment of non-small-cell lung cancer
                • Expert insight: Imfinzi
                • Key results from select clinical trials investigating Imfinzi plus Imjudo for the treatment of non-small-cell lung cancer
                • Expert insight: Imfinzi plus Imjudo
                • Key results from select clinical trials investigating Libtayo for the treatment of non-small-cell lung cancer
                • Expert insight: Libtayo
                • Key results from select clinical trials investigating Tagrisso for the treatment of non-small-cell lung cancer
                • Ongoing clinical development of Tagrisso
                • Key ongoing clinical trials of Tagrisso in the treatment of non-small-cell lung cancer
                • Expert insight: Tagrisso
                • Ongoing clinical development of erlotinib
                • Key ongoing clinical trials of erlotinib in the treatment of non-small-cell lung cancer
                • Key results from select clinical trials investigating Exkivity for the treatment of non-small-cell lung cancer
                • Ongoing clinical development of Exkivity
                • Expert insight: Exkivity
                • Rybrevant
                • Key results from select clinical trials investigating Rybrevant for the treatment of non-small-cell lung cancer
                • Ongoing clinical development of Rybrevant
                • Expert insight: Rybrevant
                • Key results from select clinical trials investigating Alecensa for the treatment of non-small-cell lung cancer
                • Ongoing clinical development of Alecensa
                • Key ongoing clinical trials of Alecensa in the treatment of non-small-cell lung cancer
                • Expert insight: Alecensa
                • Key results from select clinical trials investigating Alunbrig for the treatment of non-small-cell lung cancer
                • Ongoing clinical development of Alunbrig
                • Expert insight: Alunbrig
                • Key results from select clinical trials investigating Lorbrena / Lorviqua for the treatment of non-small-cell lung cancer
                • Ongoing clinical development of Lorbrena / Lorviqua
                • Expert insight: Lorbrena / Lorviqua
                • Key results from select clinical trials investigating Xalkori for the treatment of non-small-cell lung cancer
                • Ongoing clinical development of Xalkori
                • Key ongoing clinical trials of Xalkori in the treatment of non-small-cell lung cancer
                • Ongoing clinical development of Zykadia
                • Expert insight: Zykadia
                • Key results from select clinical trials investigating Rozlytrek for the treatment of non-small-cell lung cancer
                • Ongoing clinical development of Rozlytrek
                • Key ongoing clinical trials of Rozlytrek in the treatment of non-small-cell lung cancer
                • Expert insight: Rozlytrek
                • Key results from select clinical trials investigating Retevmo / Retsevmo for the treatment of non-small-cell lung cancer
                • Ongoing clinical development of Retevmo / Retsevmo
                • Key ongoing clinical trials of Retevmo / Retsevmo in the treatment of non-small-cell lung cancer
                • Expert insight: Retevmo
                • Key results from select clinical trials investigating Gavreto for the treatment of non-small-cell lung cancer
                • Ongoing clinical development of Gavreto
                • Key ongoing clinical trials of Gavreto in the treatment of non-small-cell lung cancer
                • Expert insights: RET inhibitors
                • Key results from select clinical trials investigating Tabrecta for the treatment of non-small-cell lung cancer
                • Ongoing clinical development of Tabrecta
                • Key ongoing clinical trials of Tabrecta in the treatment of non-small-cell lung cancer
                • Expert insight: Tabrecta
                • Key results from select clinical trials investigating Tepmetko for the treatment of non-small-cell lung cancer
                • Ongoing clinical development of Tepmetko
                • Expert insight: MET inhibitors for non-small-cell lung cancer
                • Key results from select clinical trials investigating Lumakras / Lumykras for the treatment of non-small-cell lung cancer
                • Ongoing clinical development of Lumakras / Lumykras
                • Key ongoing clinical trials of Lumakras / Lumykras in the treatment of non-small-cell lung cancer
                • Expert insight: Lumakras / Lumykras
                • Key results from select clinical trials investigating Krazati for the treatment of non-small-cell lung cancer
                • Ongoing clinical development of Krazati
                • Key ongoing clinical trials of Krazati in the treatment of non-small-cell lung cancer
                • Expert insight: Krazati
                • Key results from select clinical trials investigating Enhertu for the treatment of non-small-cell lung cancer
                • Ongoing clinical development of Enhertu
                • Key ongoing clinical trials of Enhertu in the treatment of non-small-cell lung cancer
                • Expert insight: Avastin
                • Key results from select clinical trials investigating Cyramza for the treatment of non-small-cell lung cancer
                • Ongoing clinical development of Cyramza
                • Key ongoing clinical trials of Cyramza in the treatment of non-small-cell lung cancer
              • Medical practice
                • Localized stage I/II and resectable and unresectable stage III non-small-cell lung cancer
                • First-line metastatic nonsquamous non-small-cell lung cancer
                • First-line metastatic squamous non-small-cell lung cancer
                • Second- and third-line metastatic nonsquamous non-small-cell lung cancer
                • Second- and third-line metastatic squamous non-small-cell lung cancer
                • Treatment guidelines
                • Patient characteristics influencing drug selection
                • Treatment decision tree for early-stage (stage I - III) non-small-cell lung cancer
                • Treatment decision tree for metastatic (stage IV) nonsquamous non-small-cell lung cancer with EGFR, ALK, BRAF V600E, ROS1, RET, or MET exon 14 skipping mutations
                • Treatment decision tree metastatic (stage IV) nonsquamous non-small-cell lung cancer with KRAS G12C, HER2, or EGFR exon 20 insertion mutations, or without actionable mutations
                • Treatment decision tree for metastatic (stage IV) squamous non-small-cell lung cancer
            • Unmet Need Overview
              • Current and future attainment of unmet needs in non-small-cell lung cancer
              • Top unmet needs in non-small-cell lung cancer: current and future attainment
            • Drug Pipeline
              • Pipeline
              • Regulatory milestones
              • Indication Comparison
            • Emerging Therapies
              • Key findings
                • Key emerging therapies
                  • Key therapies in development for non-small-cell lung cancer
                  • Estimated market authorization dates of key emerging therapies for the treatment of non-small-cell lung cancer
                  • Key results from select clinical trials investigating Tevimbra for the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for Tevimbra
                  • Expectations for market authorization and sales opportunity of Tevimbra in non-small-cell lung cancer
                  • Key ongoing clinical trials of retifanlimab for the treatment of non-small-cell lung cancer
                  • Analysis of clinical development program for retifanlimab
                  • Expectations for market authorization and sales opportunity of retifanlimab in non-small-cell lung cancer
                  • Key results from select clinical trials investigating Jemperli for the treatment of non-small-cell lung cancer
                  • Key ongoing clinical trials of Jemperli in the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for Jemperli
                  • Expectations for market authorization and sales opportunity of Jemperli in non-small-cell lung cancer
                  • Key results from select clinical trials investigating ivonescimab for the treatment of non-small-cell lung cancer
                  • Key ongoing clinical trials of ivonescimab in the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for ivonescimab
                  • Expectations for market authorization and sales opportunity of ivonescimab in non-small-cell lung cancer
                  • Key results from select clinical trials investigating fianlimab for the treatment of non-small-cell lung cancer
                  • Key ongoing clinical trials of fianlimab in the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for fianlimab
                  • Expectations for market authorization and sales opportunity of fianlimab in non-small-cell lung cancer
                  • Key results from select clinical trials investigating tiragolumab for the treatment of non-small-cell lung cancer
                  • Key ongoing clinical trials of tiragolumab for the treatment of non-small-cell lung cancer
                  • Analysis of clinical development program for tiragolumab
                  • Expert insight: tiragolumab
                  • Expectations for market authorization and sales opportunity of tiragolumab in non-small-cell lung cancer
                  • Key results from select clinical trials investigating vibostolimab for the treatment of non-small-cell lung cancer
                  • Key ongoing clinical trials of vibostolimab in the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for vibostolimab
                  • Expert insight: vibostolimab
                  • Expectations for market authorization and sales opportunity of vibostolimab in non-small-cell lung cancer
                  • Key ongoing clinical trials of ociperlimab in the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for ociperlimab
                  • Expectations for market authorization and sales opportunity of ociperlimab in non-small-cell lung cancer
                  • Key results from select clinical trials investigating domvanalimab for the treatment of non-small-cell lung cancer
                  • Key ongoing clinical trials of domvanalimab for the treatment of non-small-cell lung cancer
                  • Analysis of clinical development program for domvanalimab
                  • Expectations for market authorization and sales opportunity of domvanalimab in non-small-cell lung cancer
                  • Key results from select clinical trials investigating oleclumab for the treatment of non-small-cell lung cancer
                  • Key ongoing clinical trials of oleclumab in the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for oleclumab
                  • Expert insight: oleclumab
                  • Expectations for market authorization and sales opportunity of oleclumab in non-small-cell lung cancer
                  • Analysis of the clinical development program for monalizumab
                  • Expert insight: oleclumab and monalizumab in non-small-cell lung cancer
                  • Expectations for market authorization and sales opportunity of monalizumab in non-small-cell lung cancer
                  • Gotistobart
                  • Key results from select clinical trials for gotistobart
                  • Key ongoing trials of gotistobart
                  • Analysis of the clinical development program for gotistobart
                  • Expectations for market authorization and sales for gotistobart
                  • Key results from select clinical trials investigating lazertinib for the treatment of non-small-cell lung cancer
                  • Key ongoing clinical trials of lazertinib in the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for lazertinib
                  • Expert insight: lazertinib
                  • Expectations for market authorization and sales opportunity of lazertinib in non-small-cell lung cancer
                  • Key results from select clinical trials investigating aumolertinib for the treatment of non-small-cell lung cancer
                  • Key ongoing clinical trials of aumolertinib in the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for aumolertinib
                  • Expectations for market authorization and sales opportunity of aumolertinib in non-small-cell lung cancer
                  • Key results from select clinical trials investigating furmonertinib for the treatment of non-small-cell lung cancer
                  • Key ongoing clinical trials of furmonertinib in the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for furmonertinib
                  • Expectations for market authorization and sales opportunity of furmonertinib in non-small-cell lung cancer
                  • Key results from select clinical trials investigating sunvozertinib for the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for sunvozertinib
                  • Expectations for market authorization and sales opportunity of sunvozertinib in non-small-cell lung cancer
                  • Key results from select clinical trials investigating zipalertinib for the treatment of non-small-cell lung cancer
                  • Key ongoing clinical trials of zipalertinib in the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for zipalertinib
                  • Expectations for market authorization and sales opportunity of zipalertinib in non-small-cell lung cancer
                  • Key results from select clinical trials investigating ensartinib for the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for ensartinib
                  • Expectations for market authorization and sales opportunity of ensartinib in non-small-cell lung cancer
                  • Key results from select clinical trials investigating Bravtovi and Mektovi combination therapy for the treatment of non-small-cell lung cancer
                  • Expert insight: Braftovi and Mektovi
                  • Expectations for market authorization and sales opportunity of Bravtovi and Mektovi combination therapy in non-small-cell lung cancer
                  • Key results from select clinical trials investigating avutometinib for the treatment of non-small-cell lung cancer
                  • Key ongoing clinical trials of avutometinib in the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for avutometinib
                  • Expectations for market authorization and sales opportunity of avutometinib in non-small-cell lung cancer
                  • Key results from select clinical trials investigating repotrectinib for the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for repotrectinib
                  • Expert insight: repotrectinib
                  • Expectations for market authorization and sales opportunity of repotrectinib in non-small-cell lung cancer
                  • Key results from select clinical trials investigating taletrectinib for the treatment of non-small-cell lung cancer
                  • Key ongoing clinical trials of taletrectinib in the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for taletrectinib
                  • Expectations for market authorization and sales opportunity of taletrectinib in non-small-cell lung cancer
                  • Key results from select clinical trials investigating NVL-520 for the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for NVL-520
                  • Expectations for market authorization and sales opportunity of NVL-520 in non-small-cell lung cancer
                  • Key results from select clinical trials investigating savolitinib for the treatment of non-small-cell lung cancer
                  • Key ongoing clinical trials of savolitinib in the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for savolitinib
                  • Expert insight: savolitinib
                  • Expectations for market authorization and sales opportunity of savolitinib in non-small-cell lung cancer
                  • Key results from select clinical trials investigating telisotuzumab vedotin for the treatment of non-small-cell lung cancer
                  • Key ongoing clinical trials of telisotuzumab vedotin in the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for telisotuzumab vedotin
                  • Expert insight: telisotuzumab vedotin
                  • Expectations for market authorization and sales opportunity of telisotuzumab vedotin in non-small-cell lung cancer
                  • Key results from select clinical trials investigating opnurasib for the treatment of non-small-cell lung cancer
                  • Key ongoing clinical trials of opnurasib in the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for opnurasib
                  • Expert insight: emerging KRAS inhibitors
                  • Expectations for market authorization and sales opportunity of opnurasib in non-small-cell lung cancer
                  • Key results from select clinical trials investigating divarasib for the treatment of non-small-cell lung cancer
                  • Key ongoing clinical trials of divarasib in the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for divarasib
                  • Expectations for market authorization and sales opportunity of divarasib in non-small-cell lung cancer
                  • Key results from select clinical trials investigating pyrotinib for the treatment of non-small-cell lung cancer
                  • Key ongoing clinical trials of pyrotinib in the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for pyrotinib
                  • Expectations for market authorization and sales opportunity of pyrotinib in non-small-cell lung cancer
                  • Key results of select clinical trials investigating ceralasertib for the treatment of non-small-cell lung cancer
                  • Key ongoing clinical trials of ceralasertib in the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for ceralasertib
                  • Expert insight: ceralasertib
                  • Expectations for market authorization and sales opportunity of ceralasertib in non-small-cell lung cancer
                  • Key results from select clinical trials investigating tusamitamab ravtansine for the treatment of non-small-cell lung cancer
                  • Key ongoing clinical trials of tusamitamab ravtansine in the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for tusamitamab ravtansine
                  • Expert insight: use of tusamitamab ravtansine in non-small-cell lung cancer
                  • Expectations for market authorization and sales opportunity of tusamitamab ravtansine in non-small-cell lung cancer
                  • Key results from select clinical trials investigating patritumab deruxtecan for the treatment of non-small-cell lung cancer
                  • Key ongoing clinical trials of patritumab deruxtecan in the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for patritumab deruxtecan
                  • Expert insight: use of patritumab deruxtecan in non-small-cell lung cancer
                  • Expectations for market authorization and sales opportunity of patritumab deruxtecan in non-small-cell lung cancer
                  • Key results from select clinical trials investigating datopotamab deruxtecan for the treatment of non-small-cell lung cancer
                  • Key ongoing clinical trials of datopotamab deruxtecan in the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for datopotamab deruxtecan
                  • Expert insight: use of anti-TROP2 ADCs in non-small-cell lung cancer
                  • Expectations for market authorization and sales opportunity of datopotamab deruxtecan in non-small-cell lung cancer
                  • Key results from select clinical trials investigating Trodelvy for the treatment of non-small-cell lung cancer
                  • Key ongoing clinical trials of Trodelvy in the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for Trodelvy
                  • Expectations for market authorization and sales opportunity of Trodelvy in non-small-cell lung cancer
                  • Key results from select clinical trials investigating lifileucel for the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for lifileucel
                  • Expert insights: the use of lifileucel in non-small-cell lung cancer
                  • Expectations for market authorization and sales opportunity of lifileucel in non-small-cell lung cancer
                  • Key results from select clinical trials investigating OSE-2101 for the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for OSE-2101
                  • Expert insight: use of OSE-2101 in the treatment of non-small-cell lung cancer
                  • Expectations for market authorization and sales opportunity of OSE-2101 in non-small-cell lung cancer
                  • Key results from select clinical trials investigating Lenvima for the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for Lenvima
                  • Expert insight: Lenvima
                  • Expectations for market authorization and sales opportunity of Lenvima in non-small-cell lung cancer
                  • Key results from select clinical trials investigating plinabulin for the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for plinabulin
                  • Expert insight: use of plinabulin in the treatment of non-small-cell lung cancer
                  • Expectations for market authorization and sales opportunity of plinabulin in non-small-cell lung cancer
                  • Key ongoing clinical trials of Lynparza in the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for Lynparza
                  • Expert insight: Lynparza
                  • Expectations for market authorization and sales opportunity of Lynparza in non-small-cell lung cancer
                  • Key results from select clinical trials investigating Zejula for the treatment of non-small-cell lung cancer
                  • Key ongoing clinical trials of Zejula in the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for Zejula
                  • Expectations for market authorization and sales opportunity of Zejula in non-small-cell lung cancer
                  • Key results from select clinical trials investigating nogapendekin alfa (N-803) for the treatment of non-small-cell lung cancer
                  • Key ongoing clinical trials of nogapendekin alfa (N-803) in the treatment of non-small-cell lung cancer
                  • Analysis of the clinical development program for nogapendekin alfa (N-803)
                  • Expectations for market authorization and sales opportunity of nogapendekin alfa (N-803) in non-small-cell lung cancer
                • Early-phase pipeline analysis
                  • Select compounds in Phase 2 development for non-small-cell lung cancer
              • Access and Reimbursement Overview
                • Region-specific reimbursement practices
                  • Key market access considerations in NSCLC: United States
                  • General reimbursement environment: United States
                  • Key market access considerations in NSCLC: EU5
                  • General reimbursement environment: EU5
                  • Key market access considerations in NSCLC: Japan
                  • General reimbursement environment: Japan
              • Appendix
                • Abbreviations
                • Bibliography

            Login to access report